Finally, TRPM2 was found to be strongly upregulated in AML samples from patients with normal karyotypes or all AML mutational subgroups with respect to normal hematopoietic stem cells or common myeloid progenitor, suggesting the possibility to differentiate normal from neoplastic cells by using TRPM2 expression levels [49]. Here, TRPM2 is linked to acute myeloid leukemia.